Table 10.

The clinically anti-inflammatory inhibitors in cancer therapies

Drug	Target	Highest phase	Indications	Identifier	Status
Aspirin	COX-1/2	III	Gastric cancer	NCT04214990	Recruiting
		III	Colon cancer	NCT02467582	Active, not recruiting
Celecoxib	COX-2	IV	Colon cancer stage	NCT03645187	Recruiting
		IV	Hepatocellular carcinoma	NCT02961998	Completed
		IV	Bile duct cancer, pancreatic cancer	NCT01111591	Unknown
		IV	Colorectal cancer	NCT00473980	Completed
Rosuvastatin	HMG-CoA	IV	Prostate cancer metastatic	NCT04776889	Completed
Dexamethasone	Undefined	IV	Metastatic prostate cancer	NCT03432949	Recruiting
		IV	Cancer	NCT02815319	Completed
		IV	Early-stage breast cancer	NCT03348696	Completed
		IV	Pancreatic cancer	NCT04025840	Recruiting
		IV	Lung cancer	NCT02275702	Completed
		IV	Multiple myeloma	NCT01731886	Completed
		IV	Ovarian cancer	NCT00817479	Completed
		IV	Nasal and nasal-type NK/T-cell lymphoma	NCT01501149	Unknown
		IV	Relapsed refractory multiple myeloma	NCT03934684	Active, not recruiting
		IV	Peripheral T cell lymphoma	NCT03071822	Unknown
		IV	Hemophagocytic syndrome T/NK-cell lymphoma	NCT04999878	Recruiting
		Not Applicable	Mammary cancer	NCT05408676	Completed
		IV	Primary CNS lymphoma	NCT01960192	Unknown
		IV	PH+ acute lymphoblastic Leukemia	NCT02690922	Unknown
Tocilizumab	IL-6R-specific antibody	III	Refractory acute myeloid leukemia Refractory acute lymphoblastic leukemia	NCT04000698	Unknown
		III	Non-hodgkin lymphoma	NCT05171647	Recruiting
		III	Diffuse large B-cell lymphoma	NCT04408638	Recruiting
		III	Relapsed or refractory follicular lymphoma	NCT04712097	Recruiting
Siltuximab	anti-IL-6 antibody	II	Lymphoma, non-Hodgkin, multiple myeloma acute lymphoblastic leukemia	NCT04975555	Recruiting
		II	Multiple myeloma AL amyloidosis	NCT03315026	Active, not recruiting
		II	High-risk smoldering multiple myeloma	NCT01484275	Completed
		II	Multiple myeloma	NCT00402181	Completed
		II	Prostate cancer	NCT00433446	Completed
		II	Myeloma	NCT01531998	Completed
		II	Carcinoma, renal cell	NCT00265135	Completed
		II	Ovarian neoplasms, pancreatic neoplasms, colorectal neoplasms, head and neck neoplasms, lung neoplasms	NCT00841191	Completed
		II	Metastatic pancreatic adenocarcinoma, stage IV pancreatic cancer AJCC v8	NCT04191421	Completed
Itacitinib	CXCR4	IV	Lymphoma	NCT05510544	Recruiting
		IV	Non-hodgkin’s lymphoma	NCT01164475	Completed
Ruxolitinib	JAK1/2	IV	Hemophagocytic syndrome, T/NK-cell lymphoma	NCT04999878	Recruiting
Pacritinib	JAK2	II	T-Cell neoplasm lymphoproliferative disorders	NCT04858256	Recruiting
		II	Prostate cancer	NCT04635059	Recruiting
		II	Breast cancer	NCT04520269	Unknown
Bortezomib	NF-κB	IV	Multiple myeloma	NCT02268890	Completed

Source: All the information is derived from the United States Food and Drug Administration.gov (https://www.clinicaltrials.gov)